Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
Dren Investigational Site, Northridge, California Dren Investigational Site, Miami, Florida Dren Investigational Site, Evans, Georgia Dren Investigational Site, Meridian, Idaho Dren Investigational Site, Indianapolis, Indiana Dren Investigational Site, West Lafayette, Indiana Dren Investigational Site, Worcester, Massachusetts Dren Investigational Site, Troy, Michigan Dren Investigational Site, Philadelphia, Pennsylvania Dren Investigational Site, Pittsburgh, Pennsylvania Dren Investigational Site, Chattanooga, Tennessee Dren Investigational Site, San Antonio, Texas Australia
Dren Investigational Site, Charlestown, New South Wales Dren Investigational Site, Darlinghurst, New South Wales Dren Investigational Site, Coorparoo, Queensland Dren Investigational Site, South Yarra, Victoria Dren Investigational Site, Fremantle, Washington New Zealand
Dren Investigational Site, Auckland Dren Investigational Site, Christchurch Dren Investigational Site, Grafton